OpenAI Foundation disclosed a $500,000 grant to 1Day Sooner on 15 Sept 2026, earmarked for the creation of a publicly funded archive of regulatory and safety dossiers from bankrupt biotech companies. The archive is intended to feed medical‑AI models with data that are currently unavailable to researchers.
Grant details and purpose
The grant, announced in a filing reported by MIT Technology Review, will be administered by 1Day Sooner, an advocacy group that represents clinical‑trial volunteers. The money will be used to obtain detailed regulatory filings, manufacturing strategies and safety data that are typically treated as trade secrets during bankruptcy proceedings. By making non‑exclusive copies of these documents publicly available, the project seeks to create what the source calls biotech’s “lost archive.”
The Public Data for Health initiative
The funding is part of OpenAI Foundation’s newly launched Public Data for Health effort, which aims to accelerate AI breakthroughs in medicine by financing the creation of high‑quality scientific datasets. The initiative reflects a broader industry view that data scarcity, rather than model size, limits AI’s impact on biology.
“Everyone is recognizing that data is the biggest bottleneck in successfully applying AI to biology,” says Morgan Levine, a former vice president for computation at Altos Labs.
Levine’s comment, cited in the same MIT Technology Review article, underscores the strategic rationale behind the grant: without richer, real‑world biomedical data, AI models cannot achieve the predictive power needed for drug‑development tasks.
Who is behind the effort
OpenAI Foundation is the nonprofit parent of OpenAI, the artificial‑intelligence research lab headquartered in San Francisco. The foundation’s chief executive is Sam Altman, and the organization employs roughly 4,500 staff members, according to Wikidata. 1Day Sooner, while lacking publicly listed leadership or employee figures, is known for its work on clinical‑trial volunteer advocacy and for supporting policy ideas such as the one proposed by Ruxandra Teslo, a policy analyst who focuses on clinical trials.
Teslo’s proposal, first outlined last year, suggested that bidders at bankruptcy proceedings could acquire the detailed dossiers of failed biotech firms. She argued that these documents could serve as training material for AI systems that act as “copilots” in the drug‑approval process, potentially reducing the opacity that currently hampers efficient drug development.
Implications for medical AI and biotech
If successful, the archive could become a unique resource for researchers building AI models that predict drug safety, efficacy or manufacturing challenges. By providing access to data that were previously locked behind trade‑secret protections, the project may lower the barrier to entry for smaller AI labs and academic groups that lack the capital to purchase proprietary datasets.
The initiative also signals a shift in how AI firms view collaboration with the life‑science sector. Rather than solely investing in proprietary data pipelines, OpenAI is funding an open‑access effort, which could set a precedent for other technology companies seeking to influence biomedical research.
Open questions
- How quickly 1Day Sooner can secure the targeted dossiers remains unclear; the filing does not specify a timeline for data acquisition.
- The legal framework for extracting and publishing non‑exclusive copies of bankruptcy‑related documents has not been detailed, leaving potential regulatory hurdles unaddressed.
- It is not yet known how the broader AI‑research community will integrate the archive into existing training pipelines, or whether the data will be sufficient to produce measurable improvements in model performance.
| Item | Value | Source |
|---|---|---|
| Grant amount | USD 500,000 | MIT Technology Review |
| Recipient | 1Day Sooner | MIT Technology Review |
| Announcement date | 15 Sept 2026 | MIT Technology Review |
| Program | Public Data for Health | MIT Technology Review |
OpenAI Foundation’s $500,000 grant marks a concrete step toward expanding the data foundation for medical AI. Whether the “lost archive” will materialise into a usable dataset, and how quickly it will influence drug‑development research, will become clearer as 1Day Sooner moves forward with the bankruptcy‑filing acquisition process.